July 07, 2026 09:19 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
China tests ballistic missile from nuclear submarine in Pacific: Australia, New Zealand respond | Baruipur horror: Main accused in alleged rape and murder of minor girl arrested; senior cops dissatisfied with handling of the case | Defence stocks jump after Rs 52,000 crore DAC approval sparks buying frenzy | 'Harry Kane is a great player': Donald Trump after England knocked Mexico out of the World Cup | 'Referee gave a lot against us': Harry Kane reacts after England's dramatic win over Mexico | England hold nerve with 10 men to knock out Mexico in five-goal World Cup classic | 'Why can't citizens protest against the government? They are being made slaves by slapping cases': Bombay HC slams Mumbai Police, quashes activist's externment | 'First he cheats on me...': Siya Goyal's old pub video goes viral amid probe into fiancé Ketan Agarwal's alleged murder | Ronaldo's goal, Ramos' last-gasp winner send Portugal past Croatia, set up Spain clash | India-US trade deal almost done! Piyush Goyal hints at breakthrough
Covaxin

Brazil denies permission to import Bharat Biotech developed Covaxin

| @indiablooms | Apr 01, 2021, at 04:41 am

New Delhi/IBNS:  Brazil's health regulator has denied permission to import Covaxin, the coronavirus vaccine developed by India's indigenous firm Bharat Biotech.

According to reports, a Brazilian government gazette had said that Covaxin had been rejected "considering the non-compliance with the requirements of Good Manufacturing Practices for Medicines''.

In its response to the same, Bharat Biotech has told NDTV: ''The requirements pointed out during inspection will be fulfilled, the timelines for fulfilment is under discussion with the Brazil NRA and will be resolved soon.''

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research.

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

Bharat Biotech said the vaccine is effective against the UK variant of the virus.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.